Literature DB >> 34285050

Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA's Adverse Event Reporting System.

Maximilian Pistor1, Andreas G F Hoepner2,3, Yanan Lin2, Simon Jung1, Claudio L Bassetti1, Andrew Chan1, Anke Salmen1, Robert Hoepner4.   

Abstract

Entities:  

Keywords:  COVID-19; autoimmune diseases; biological therapy; therapeutics

Year:  2021        PMID： 34285050     DOI： 10.1136/annrheumdis-2021-220679

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  3 in total

1.  Is COVID-19 severity associated with reduction in T lymphocytes in anti-CD20-treated people with Multiple Sclerosis or Neuromyelitis Optica Spectrum Disorder?

Authors:  Robert Hoepner; Christian P Kamm; Christoph Friedli; Anke Salmen; Andrew Chan
Journal:  CNS Neurosci Ther       Date:  2022-04-12       Impact factor: 7.035

2.  Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study.

Authors:  Zara Izadi; Milena A Gianfrancesco; Gabriela Schmajuk; Lindsay Jacobsohn; Patricia Katz; Stephanie Rush; Clairissa Ja; Tiffany Taylor; Kie Shidara; Maria I Danila; Katherine D Wysham; Anja Strangfeld; Elsa F Mateus; Kimme L Hyrich; Laure Gossec; Loreto Carmona; Saskia Lawson-Tovey; Lianne Kearsley-Fleet; Martin Schaefer; Samar Al-Emadi; Jeffrey A Sparks; Tiffany Y-T Hsu; Naomi J Patel; Leanna Wise; Emily Gilbert; Alí Duarte-García; Maria O Valenzuela-Almada; Manuel F Ugarte-Gil; Lotta Ljung; Carlo A Scirè; Greta Carrara; Eric Hachulla; Christophe Richez; Patrice Cacoub; Thierry Thomas; Maria J Santos; Miguel Bernardes; Rebecca Hasseli; Anne Regierer; Hendrik Schulze-Koops; Ulf Müller-Ladner; Guillermo Pons-Estel; Romina Tanten; Romina E Nieto; Cecilia N Pisoni; Yohana S Tissera; Ricardo Xavier; Claudia D Lopes Marques; Gecilmara C S Pileggi; Philip C Robinson; Pedro M Machado; Emily Sirotich; Jean W Liew; Jonathan S Hausmann; Paul Sufka; Rebecca Grainger; Suleman Bhana; Monique Gore-Massy; Zachary S Wallace; Jinoos Yazdany
Journal:  Lancet Rheumatol       Date:  2022-07-25

3.  Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System.

Authors:  Maximilian Pistor; Robert Hoepner; Andreas G F Hoepner; Yanan Lin; Simon Jung; Claudio L Bassetti; Andrew Chan; Anke Salmen
Journal:  Ther Adv Neurol Disord       Date:  2022-10-10       Impact factor: 6.430
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.